Melanoma Treatment Options and Margin Control

The Direct Answer: Melanoma Treatment Is a Sequence of Decisions

Melanoma treatment is not one operation. It is a sequence:

1. define what the pathology report actually shows;
2. clear the primary tumor with the right margin strategy;
3. decide whether lymph-node staging would change care; and
4. add systemic therapy or surveillance when stage and risk justify it.

A melanoma in situ on the cheek and a 3-mm ulcerated melanoma on the back share a disease family, but not a treatment pathway. The first may be primarily a margin-mapping problem. The second is both a local-surgery and regional-staging problem.

Think of melanoma care like planning a trip with three maps. The first map shows the edge of the original tumor. The second shows the regional lymphatic route. The third shows the rest of the body. Good care uses the map that matches the question rather than forcing every patient onto the same road.

What Is Melanoma?

Melanoma begins in melanocytes, the cells that make pigment. It often begins in the skin, although melanomas can also arise in the eye or on mucosal surfaces. This guide concerns cutaneous melanoma, or melanoma of the skin.^1–3

Melanoma matters because it can spread through lymphatic channels or blood. Most early melanomas are cured with appropriate surgery. The likelihood of spread rises with features such as greater depth, ulceration, regional deposits, lymph-node involvement, and distant disease.^1–3

Melanoma in situ versus invasive melanoma

• Melanoma in situ is confined to the epidermis, the outer layer of skin. It has no direct access to lymphatic or blood vessels in deeper skin and is treated as a local margin problem.
• Invasive melanoma has entered the dermis. Once invasive, depth and other pathologic features help determine the surgical margin, whether sentinel-node biopsy should be discussed, and the risk of recurrence elsewhere.^1–3

The phrase stage 0 is commonly used for melanoma in situ. Stages I and II generally describe localized invasive melanoma. Stage III includes regional lymph nodes, microsatellites, satellites, or in-transit disease. Stage IV means distant spread. Stage describes extent; it does not prescribe one identical treatment for everyone.^1–3

The Pathology Report Sets the First Branch

The pathology report is the first treatment map. The most important features include:

• in situ versus invasive disease;
• Breslow thickness, measured in millimeters to the deepest melanoma cell;
• ulceration;
• mitotic rate;
• margin status;
• melanoma subtype;
• microsatellites;
• lymphovascular or perineural involvement;
• regression; and
• whether the biopsy may have transected the deepest part of the tumor.^1–4

Breslow thickness

Breslow thickness is not the width seen on the skin. It is the microscope measurement from the top reference point of the epidermis to the deepest invasive melanoma cell. A 0.4-mm melanoma and a 4-mm melanoma may look similar at the surface while having very different staging and treatment implications.^1,2

Ulceration

Ulceration means the epidermis over the melanoma is truly absent under the microscope because of tumor biology, not merely injured by biopsy. It raises T category and prognosis at a given depth.^1,2

Features that add context

Mitotic rate remains useful even though it no longer defines T1 substaging by itself. Microsatellites—separate microscopic deposits near the primary tumor—establish regional disease and at least stage III. Regression alone is not a reason to perform sentinel-node biopsy. Desmoplastic melanoma should be classified as pure or mixed because nodal behavior differs, and a partial biopsy can miss the mixed component.^1,3,4

Treatment Options at a Glance

Surgery for Localized Melanoma

Surgery is the usual first treatment for localized melanoma. The goal is to remove the tumor and an evidence-based rim of clinically normal-appearing skin while preserving function and avoiding unnecessary sacrifice.^2,3

These are clinical margins measured on the patient. They are not guaranteed microscopic clearance distances, and they do not mean that every site must be reconstructed in the same way.

Wider is not automatically better

For melanomas thicker than 2 mm, a randomized multicenter trial compared 2-cm and 4-cm margins. After nearly 20 years, melanoma-specific survival was essentially the same, with a hazard ratio of 0.95.⁵

Why Melanoma in Situ Can Require Different Margin Strategies

No randomized trial defines one perfect margin for all melanoma in situ. A small, sharply defined lesion on the trunk may clear with a 5-mm margin. A large lentigo maligna on sun-damaged facial skin may extend microscopically well beyond what the eye can see.^2,3,6–8

When a standard margin can fit

For a small, well-defined melanoma in situ on a lower-risk site, standard excision with an appropriate margin is reliable. A 2024 cohort supports 5-mm margins for carefully selected small lesions in suitable locations.⁷

Why head-and-neck melanoma often needs mapping

In a 10-year series of 846 head-and-neck melanoma-in-situ cases treated with Mohs, only 62% cleared at 5 mm. Clearance reached 97% by 15 mm.⁸

That does not mean every facial melanoma needs a 15-mm circle removed at the first operation. It means the opposite: an iterative map can follow the true microscopic edge rather than guessing a large uniform margin in advance.

When Mohs Surgery May Be the Strongest Local Strategy

Mohs surgery for melanoma is not simply the same operation used for BCC with a different label. It requires melanoma-specific pathology, immunostains, workflow, and judgment.

In a typical margin-controlled melanoma procedure:

1. the clinically visible tumor or central debulk is removed;
2. the peripheral and deep margins are mapped;
3. immunostains such as MART-1, SOX10, or PRAME help identify melanocytes at the margin;
4. additional tissue is removed only where the map remains positive; and
5. the central specimen undergoes permanent-section pathology to preserve definitive depth, ulceration, subtype, and staging information before reconstruction.^9–16

Mohs or staged excision is especially compelling for:

• lentigo maligna or melanoma in situ on chronically sun-damaged head-and-neck skin;
• large or poorly defined melanoma in situ;
• recurrent melanoma in situ;
• acral melanoma where preserving a digit, palm, or sole matters;
• selected minimally invasive T1a melanoma in a constrained site;
• tumors whose visible border is unreliable; and
• cases where reconstruction should begin only after complete margin mapping.^2,3,9,10

Local recurrence: Mohs compared with wide local excision

In a nonrandomized cohort of 662 melanomas in situ followed for a median of 8.6 years, recurrence was 1.8% after Mohs and 5.7% after wide local excision. Five-year recurrence was 1.1% versus 4.1%.²⁹

A 2022 systematic review and meta-analysis also found higher local recurrence after wide local excision than after Mohs or staged excision.⁹ A 2025 systematic review of invasive melanoma treated with Mohs likewise found low recurrence in appropriately selected cases.¹⁰

Survival evidence is favorable, not merely reassuring

Two large adjusted registry studies directly challenge the outdated idea that Mohs compromises melanoma survival:

• In a National Cancer Database analysis of stage I invasive melanoma adjusted for patient and tumor characteristics, Mohs was associated with better overall survival than wide local excision, hazard ratio 0.86 through follow-up extending to 10 years.³⁰
• In a SEER study of 20,451 invasive head-and-neck melanomas, five-year disease-specific survival was 92% after Mohs and 82% after wide local excision. Ten-year disease-specific survival was 87% versus 74%, and adjusted mortality remained higher after wide local excision.³¹

Mohs and Wide Local Excision: A Clear Comparison

This is not a contest in which one operation must replace the other everywhere. Wide local excision remains excellent for most invasive melanoma. Mohs becomes the stronger choice when the tumor is a mapping problem and when a specialized team can preserve staging while examining the complete margin.

Will I Need a Sentinel Lymph-Node Biopsy?

Sentinel lymph-node biopsy, or SLNB, samples the first draining lymph node or nodes to look for microscopic regional melanoma. It is mainly a staging procedure. It does not replace removal of the primary tumor.^1,3,17

A practical threshold framework

• Uncomplicated T1a melanoma under 0.8 mm without ulceration: routine SLNB is not recommended.
• T1b melanoma and selected T1a melanoma with adverse features or uncertain depth: discuss the probability of a positive node, procedural burden, and what the result would change.
• Melanoma thicker than 1 mm: generally offer or discuss SLNB when the result will change staging, adjuvant treatment, or surveillance.^1,3,17

SLNB is not automatically therapeutic. MSLT-I showed that sentinel-node status is strongly prognostic, while the randomized biopsy strategy did not improve melanoma-specific survival across the entire study population.¹⁷

The practical value is information: a positive result changes stage and may open adjuvant treatment or closer surveillance. A negative result reduces, but does not eliminate, the possibility of recurrence.

What Happens After a Positive Sentinel Node?

A positive sentinel node no longer means that every remaining lymph node in the basin must automatically be removed.

MSLT-II and DeCOG-SLT compared immediate completion lymph-node dissection with active nodal observation. The larger operation did not improve melanoma-specific survival and caused more lymphedema.^18,19

When Drug Treatment Enters After Surgery

Adjuvant treatment aims to eliminate microscopic melanoma that may remain after all visible disease has been removed. It is not needed for every localized melanoma. The expected recurrence risk must justify treatment burden and toxicity.

Stage IIB and IIC

In KEYNOTE-716, adjuvant pembrolizumab improved 48-month recurrence-free survival from 58.3% to 71.3%, with a hazard ratio of 0.62.²⁰

That is a meaningful reduction in recurrence. Overall-survival benefit has not yet been demonstrated in this population. Patients should understand both facts: the drug lowers recurrence risk, and it can cause immune side effects that occasionally persist.

Stage III

Adjuvant anti-PD-1 therapy improves recurrence-free survival after resection of stage III melanoma.^20,21 Patients with a BRAF V600 mutation may also have a targeted BRAF/MEK option. The choice depends on mutation status, autoimmune history, recurrence risk, toxicity profile, pregnancy considerations, and preference.

When Treatment Before Surgery Makes Sense

For selected resectable macroscopic stage III melanoma, systemic treatment before surgery can expose the intact tumor and lymph nodes to therapy, reveal whether the melanoma responds, and guide postoperative treatment.

In the NADINA strategy trial, neoadjuvant ipilimumab plus nivolumab followed by surgery and response-adapted postoperative management produced 12-month event-free survival of 83.7%, compared with 57.2% after surgery followed by adjuvant nivolumab. The hazard ratio was 0.32.²²

Treatment for Advanced Melanoma

Advanced melanoma treatment can include immune checkpoint therapy, BRAF/MEK targeted therapy when a BRAF V600 mutation is present, tumor-infiltrating lymphocyte therapy, radiation, surgery for selected local problems, and clinical trials.

Immune checkpoint therapy

In CheckMate 067, 10-year overall survival was:

The combination produced the highest survival and substantially more severe treatment toxicity.²³ The decision is not “strong drug versus weak drug.” It is the probability of durable control weighed against the probability and consequence of immune injury.

BRAF-mutant melanoma

BRAF/MEK targeted therapy can shrink BRAF V600-mutant melanoma quickly. For eligible untreated advanced disease, DREAMseq supports starting with nivolumab plus ipilimumab rather than targeted therapy because treatment sequence affected longer-term outcomes.²⁴ Rapidly threatening disease or contraindications to immunotherapy can change that sequence.

Tumor-infiltrating lymphocyte therapy

TIL therapy can produce responses after checkpoint therapy in selected patients. It is intensive, requires specialized centers, and should be discussed in the context of the exact product and evidence rather than as a generic last-resort label.²⁵

When Radiation Is Used

Radiation is not the usual primary treatment for an operable localized cutaneous melanoma. It can be valuable for:

• selected brain metastases;
• painful bone or soft-tissue disease;
• unresectable local or regional disease;
• selected postoperative nerve or nodal risk;
• local control of oligometastatic disease; and
• symptom relief alongside systemic therapy.^2,3

The modern melanoma plan often combines tools. Surgery controls a resectable anatomic target. Systemic therapy treats invisible or distributed disease. Radiation can control a focused site that needs rapid or durable local treatment.

When Surgery or More Treatment May Not Be Necessary

Decisive care includes knowing when not to escalate.

• A small, well-defined melanoma in situ on a lower-risk site may not need Mohs if standard excision can reliably clear it with acceptable function.
• An uncomplicated T1a melanoma under 0.8 mm without ulceration usually does not need sentinel-node biopsy.
• A positive sentinel node usually does not require completion dissection.
• Asymptomatic stage IA-IIA disease usually does not need routine surveillance imaging.
• An early localized melanoma that has been completely treated does not automatically need immunotherapy.^{1–3,18–20}

The goal is not maximum treatment. It is complete treatment of the actual risk.

Follow-Up After Melanoma

Follow-up should detect treatable recurrence, identify a second primary melanoma, manage therapy effects, and teach skin and lymph-node awareness without turning low-yield testing into routine harm.³

Routine imaging is not recommended for asymptomatic stage IA-IIA melanoma. Selected stage IIB-IV patients may receive time-limited imaging depending on stage, symptoms, prior treatment, and whether a finding would change care.³

Melanoma survivors retain a lifelong risk of another primary melanoma. A large SEER cohort reported a second melanoma in 3.9% by five years and 6.7% by ten years.²⁶

Patients should know what to report between visits:

• a new or changing skin lesion;
• a lump near the original melanoma or regional lymph-node basin;
• unexplained persistent pain;
• neurologic change;
• persistent cough or shortness of breath;
• unexplained weight loss; or
• another symptom that is new, progressive, and unexplained.

A Practical Treatment Framework

Five Common Patient Examples

1. A small melanoma in situ on the lower leg

If borders are sharp and an appropriate margin is practical, standard excision may be exactly right. Mohs is not required merely because the diagnosis is melanoma.

2. A broad lentigo maligna on the cheek

This is a classic margin-mapping problem. Mohs or staged excision can trace the true edge, preserve uninvolved cheek tissue, and confirm clearance before reconstruction.

3. A 0.6-mm nonulcerated melanoma on the back

The usual plan is a 1-cm surgical margin. Routine sentinel-node biopsy is generally unnecessary if it is uncomplicated T1a disease and the depth is reliable.

4. A 1.7-mm melanoma on the arm

Surgery uses a 1- to 2-cm margin, and sentinel-node biopsy should be discussed because the result can change stage and adjuvant treatment.

5. A palpable stage III melanoma in a lymph node

The patient should be evaluated by a coordinated melanoma team before an automatic operation. Neoadjuvant immunotherapy may improve event-free survival and allow pathologic response to guide the rest of treatment.

Questions to Ask Before Choosing Treatment

1. Is this melanoma in situ or invasive?
2. What is the exact Breslow thickness and is ulceration present?
3. Was the deepest portion sampled, or is the depth uncertain?
4. What clinical margin is recommended, and why?
5. Would complete margin mapping with Mohs or staged excision improve clearance or tissue preservation at this site?
6. If Mohs is used, how will the central tumor receive permanent-section staging?
7. Should sentinel-node biopsy be discussed, and what would the result change?
8. Is molecular testing, including BRAF status, relevant now?
9. Would treatment before or after surgery reduce recurrence risk?
10. What follow-up is useful, and which scans would actually change care?

Next Steps in the Patient Journey

• Read What Does My Skin Biopsy Report Mean? to review the pathology terms that change melanoma staging and treatment.
• Continue to Low-Risk vs High-Risk Skin Cancer to understand why the same diagnosis can follow different care pathways.
• Read Mohs Surgery vs Standard Excision when margin strategy is an active treatment decision.
• Use How Will My Skin Cancer Wound Be Repaired? after the cancer-clearance plan is settled.
• Share this guide with your treating dermatologist and ask how the margins, lymph nodes, and systemic-treatment decisions fit together.